We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioLineRx, MaRS Innovation Sign Framework Collaboration Agreement
News

BioLineRx, MaRS Innovation Sign Framework Collaboration Agreement

BioLineRx, MaRS Innovation Sign Framework Collaboration Agreement
News

BioLineRx, MaRS Innovation Sign Framework Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioLineRx, MaRS Innovation Sign Framework Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioLineRx Ltd has announced that it has signed a framework collaboration agreement with MaRS Innovation, the commercialization agent for fifteen of Toronto's top academic institutions. Under the terms of the agreement, BioLineRx intends to review innovative projects and assets of startup companies originating from MaRS Innovation's members, in order to identify in-licensing, co-development or other partnering opportunities.

Kinneret Savitsky, Ph.D., CEO of BioLineRx, said, "We are pleased to collaborate with MaRS Innovation, one of the largest technology transfer organizations in North America. MaRS Innovation represents and invests in early stage assets derived from 15 institutions in Ontario, Canada, including the University of Toronto and its 9 affiliated teaching hospitals. We view them as a valuable source of potential innovative technologies and look forward to working together towards the development of future therapies."

"BioLineRx has a proven track record of identifying promising early stage biomedical projects and successfully developing them through clinical stages," stated Dr. Raphael Hofstein, President and CEO, MaRS Innovation. "We believe that the combination of our pool of novel technologies and projects together with BioLineRx's drug development expertise and strategic collaborations with global players is a perfect match."

Advertisement